ABSTRACT Some of the previously reported clinical isolates of Elizabethkingia meningoseptica may be later named species of Elizabethkingia. We determined the accuracy of species identification (with two matrix-assisted laser desorption ionizationtime of flight mass spectrometry [MALDI-TOF MS] systems and the Vitek 2 GN card), relative prevalence of three Elizabethkingia spp. in clinical specimens, and antimicrobial susceptibility of the species identified by 16S rRNA gene sequencing. Specimens for culture were collected from patients in a university hospital in Seoul, South Korea, between 2009 and 2015. All 3 Elizabethkingia spp. were detected in patients; among the 86 isolates identified by 16S rRNA gene sequencing, 17 (19.8%) were E. meningoseptica, 18 (20.9%) were Elizabethkingia miricola, and 51 (59.3%) were Elizabethkingia anophelis. Only the MALDI-TOF Vitek MS system with an amended database correctly identified all of the isolates. The majority (76.7%) of the isolates were from the lower respiratory tract, and 8 (9.3%) were from blood. Over 90% of E. meningoseptica and E. anophelis isolates were susceptible to piperacillin-tazobactam and rifampin. In contrast, all E. miricola isolates were susceptible to fluoroquinolones except ciprofloxacin. Further studies are urgently needed to determine the optimal antimicrobial agents for the treatment of infections due to each individual Elizabethkingia species.
case of E. miricola sepsis was reported in 2008 (10) , and a case of E. anophelis neonatal meningitis was reported in 2013 (11) .
E. meningoseptica isolates are often resistant (R) to multiple ␤-lactam antibiotics due to intrinsic class A extended-spectrum ␤-lactamases (ESBLs) and inherent class B metallo-␤-lactamases (MBLs) (12) . The antimicrobial susceptibility of Elizabethkingia may vary depending on the species. However, there are scanty data on the susceptibility of the new species. The aims of this study were to determine the accuracy of species identification systems and the relative prevalence of three Elizabethkingia spp. in clinical specimens and to compare the antimicrobial susceptibility of the species identified by 16S rRNA gene sequencing.
RESULTS
Elizabethkingia spp. identified. Among the total 86 Elizabethkingia isolates, the species identified using 16S rRNA gene sequencing were 17 isolates (19.8%) of E. meningoseptica (99.5% to 99.9% nucleotide identity to E. meningoseptica type strain ATCC 13253), 18 isolates (20.9%) of E. miricola (98.9% to 99.8% nucleotide identity to E. miricola type strain GTC862), and 51 isolates (59.3%) of E. anophelis (99.1% to 100.0% nucleotide identity to E. anophelis type strain FMS-007).
The matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) Vitek MS system with an amended database correctly identified all of the 17, 18, and 51 isolates of E. meningoseptica, E. miricola, and E. anophelis, respectively. However, the Bruker Biotyper correctly identified 16 of 17 E. meningoseptica isolates and 17 of 18 E. miricola isolates but none of the E. anophelis isolates ( Table 1 ). The Vitek 2 GN card system correctly identified 16 of 17 E. meningoseptica isolates but none of the other species.
Among the 86 isolates of Elizabethkingia spp., 66 (76.7%) were recovered from the lower respiratory tract, 8 (9.3%) from blood, 7 (8.1%) from urine, and 5 (5.8%) from other specimens ( Table 2) . Among the 8 isolates from blood, 2 isolates were identified as E. miricola and 6 isolates were identified as E. anophelis. There were no E. meningoseptica isolates from blood. Careful clinical evaluation suggested that the positive blood (Table 3 ). All of the 8 patients had various underlying diseases and had indwelling catheters or endotracheal tubes. Four patients were admitted to the ICU. All of the patients, except for one, were treated with various antimicrobial agents during the 7 days prior to blood culture. Among the four patients, two were cured with tigecycline and trimethoprimsulfamethoxazole, to which the isolates were susceptible (S). The remaining two patients were cured with trimethoprim-sulfamethoxazole, although the MICs for the isolates were 4 and 76 g/ml (resistance breakpoints, Ն4 and 76 g/ml), respectively. In pulsed-field gel electrophoresis (PFGE) analysis, isolates of each Elizabethkingia species belonged to 5 to 10 different PFGE groups, while identical pulsotypes were found in 8 of 17 E. meningoseptica isolates, 6 of 18 E. miricola isolates, and 17 of 51 E. anophelis isolates (see Fig. S1 in the supplemental material).
Antimicrobial susceptibilities. The MICs of the antimicrobial agents and the susceptibilities of the isolates are shown in Table 4 (see Data Set S1 in the supplemental material). Among the E. meningoseptica isolates, 100% and 94% were susceptible to piperacillin-tazobactam and rifampin, respectively, but only 23% to 41% were susceptible to fluoroquinolones. Unlike E. meningoseptica, all E. miricola isolates were susceptible to fluoroquinolones, except for ciprofloxacin. Over 90% of E. meningoseptica and E. anophelis isolates were susceptible to piperacillin-tazobactam and rifampin. Although none of the species were susceptible to vancomycin, all three species exhibited at least 94% intermediate (I) reaction to this agent.
DISCUSSION
The accuracy of species identification was low with the Vitek 2 GN card system. Although our Bruker Biotyper without an amended database failed to identify E. anophelis isolates, the addition of a database for E. anophelis was recently reported (13) . This result indicates that a MALDI-TOF mass spectrometry (MS) system can be a reliable species identification system for the genus Elizabethkingia.
Although E. meningoseptica infections are well known, E. miricola sepsis in a lymphoma patient was reported in the United States after the proposal of new species (10) . Several E. anophelis infections have been reported from tropical or subtropical regions, the Central African Republic (11), Singapore (14) , and Hong Kong (15) . A recent study in Hong Kong urged researchers to consider the clinically significant morbidity and mortality of patients with E. anophelis bacteremia (13) . An E. anophelis outbreak in Wisconsin in 2016 resulted in the deaths of at least 18 patients (16).
In our study, which took place in the temperate country of South Korea, all three species of Elizabethkingia were detected in patients, and E. anophelis was the most prevalent. It is interesting that E. meningoseptica was not present while E. anophelis was the most common among blood isolates (Table 2 ). These findings suggest that E. anophelis plays a significant role as a human pathogen. In general, the majority of blood isolates are clinically significant (5, 13, 16). However, in our study, only 4 of the 8 patients with positive Elizabethkingia blood cultures were clinically significant, although all of the patients had risk factors for infection (Table 3 ). The majority of the Elizabethkingia isolates were detected in lower respiratory tract specimens, but it was difficult to distinguish infection from colonization as reported in other studies (4, 17) .
Our PFGE analysis of each species showed that certain pulsotypes were more prevalent than others, suggesting that these types are either more prevalent in the hospital environment or that they have a higher capability to infect or colonize.
E. meningoseptica has been known to be resistant to multiple antimicrobial agents (18, 19) . However, as mentioned above, the susceptibility of E. meningoseptica in the previous study may include those of the other 2 species. To the best of our knowledge, our study is the first one to compare the susceptibilities of all Elizabethkingia species (Table 4) . The organisms are typically resistant to ␤-lactams (15, 18) . In a previous study from our group (19) , all 31 isolates of E. meningoseptica (which may include other Elizabethkingia species) g Microbiologic eradication was the absence of the original pathogens detected from blood (7 days after the first positive blood culture). h Clinical response: a favorable clinical response was defined as the resolution of fever (defined as Ն38.0°C), leukocytosis (WBC, Ն11 ϫ 10 6 /l), and hypotension (mean arterial pressure of Ͻ65 mm Hg), in addition to no longer requiring support from vasoactive agents. Patients who had persistence or deterioration in clinical parameters or who died were classified as treatment failures. i NA, not applicable. There was no follow up data due to transfer of the patient within 7 days.
had both bla BlaB and bla GOB genes. The GenBank database shows that chromosomes of E. anophelis (accession numbers CP006576 and CP007547) and E. miricola (accession number CP011059) possess bla BlaB , bla GOB , and bla CME genes and an AmpC ␤-lactamase gene. In our study, over 90% of the isolates of 3 Elizabethkingia spp. were susceptible to a piperacillin-tazobactam combination. This has also been shown by other studies (5, 20) . However, it is necessary to evaluate clinical efficacy, given that all Elizabethkingia spp. appear to be inherent MBL producers.
Antimicrobial resistance may vary depending on the species as well as the region and time of bacterial isolation. As mentioned above, limited data are currently available on the susceptibility patterns of Elizabethkingia spp. Although three previous studies were performed using relatively significant numbers of isolates, the specimens were from unspecified sources of patients, blood, or hospital environments (5, 21, 22) . Furthermore, all three reports stated that the species were E. meningoseptica, but the isolates were identified before the proposal of new species or unreliable phenotypic methods were used for identification. However, by comparing our results, based on a The interpretive criteria applied were those of the CLSI for non-Enterobacteriaceae; the criteria for vancomycin and rifampin were those for Staphylococcus or Enterococcus spp. The criterion of gatifloxacin was that for moxifloxacin. b In the combinations, the concentration of tazobactam was 4 g/ml constant, and the ratio of trimethoprim to sulfamethoxazole was 1 to 19.
identification by 16S rRNA sequencing, to those of other studies, the following generalization can be made: Elizabethkingia spp. are nonsusceptible to ceftazidime, imipenem, and vancomycin (high vancomycin susceptibility in a study may be due to the use of a higher breakpoint, 16 g/ml [21] ); the susceptibility rates of E. miricola to fluoroquinolones are higher than those of the other species; and the susceptibility of Elizabethkingia spp. to other antimicrobial agents are difficult to predict. Several reports have shown that the incidence of Elizabethkingia bacteremia increased and the mortality rate was high (5, 20, 23, 24) . Indwelling devices and inappropriate antimicrobial therapy were independent risk factors for poor outcomes with Elizabethkingia bacteremia (5, 24, 25) . In our study, all 4 bacteremic patients were microbiologically cured with trimethoprim-sulfamethoxazole alone or with a combination of tigecycline plus trimethoprim-sulfamethoxazole or ciprofloxacin. Anecdotal reports have indicated that some cases of E. meningoseptica infection respond only to combinations of piperacillintazobactam plus rifampin, vancomycin plus rifampin, or a fluoroquinolone plus vancomycin and rifampin (6) . In our study, none of the Elizabethkingia isolates were susceptible to vancomycin, and the majority were intermediate, indicating similar susceptibility with those of the worldwide collection from 1999 to 2001 (22) . Therefore, it seems that vancomycin alone is ineffective in the treatment of Elizabethkingia infection.
In conclusion, E. anophelis was the most frequently detected species in clinical specimens. Over 90% of 3 Elizabethkingia spp. were susceptible to piperacillintazobactam. The majority of E. meningoseptica and E. anophelis isolates were susceptible to rifampin, and all isolates of E. miricola only were susceptible to levofloxacin, moxifloxacin, and gatifloxacin. Therefore, further studies are urgently needed to determine the optimal antimicrobial agents for treatment of infections caused by each individual Elizabethkingia species.
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